|

Metabolically Armed TIL cells Clinical Trials

2 actively recruiting trials

Also known as: Meta10-TIL

Pipeline

Early 1: 2

Top Sponsors

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
  • Anhui Provincial Hospital1

Indications

  • Advanced Solid Tumors2
  • Cancer2
  • Liver Disease1
  • Liver Cancer1

Other2 trials

Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Early 1
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.